Why the study?
It is unclear whether early detection of hypertension through screening leads to healthier behaviours and better blood pressure control, requiring evaluation of different screening approaches on patient-important outcomes.
Do different screening strategies (mass, targeted or opportunistic) for hypertension reduce morbidity and mortality?
Do different screening strategies (mass, targeted or opportunistic) for hypertension reduce morbidity and mortality?
Answers are grounded in this paper and cite their sources.
This protocol outlines a systematic review to evaluate the comparative effectiveness of mass, targeted, or opportunistic screening strategies for hypertension.
INTRODUCTION: It is unclear whether early detection of hypertension, through screening, leads to healthier behaviours and better control of blood pressure levels. There is a need to learn from studies that have assessed the impact of different screening approaches on patient important outcomes. This systematic review protocol outlines the methods that will be used to assess the comparative effectiveness of different screening strategies (mass, targeted or opportunistic) for hypertension to reduce morbidity and mortality associated with hypertension. METHODS AND ANALYSIS: We will primarily search Cochrane Central Register of Controlled Trials, Medline, Embase and Latin American and Caribbean Health Sciences Literature (LILACS). Relevant randomised controlled trials, controlled before and after, interrupted time series and prospective analytic cohort studies regardless of publication date, language and geographic location, will be included. We are interested in clinical, adverse event and health system outcomes. Two reviewers will independently screen titles, abstracts and full-text articles against inclusion criteria; perform data extraction and assess risk of bias in included studies. We will assess the certainty of the overall evidence using the Grading of Recommendations Assessment, Development and Evaluation approach and report findings accordingly. ETHICS AND DISSEMINATION: No ethics approval will be sought, as only secondary studies will be used. Findings will be disseminated through peer-reviewed publication and conference presentations. PROSPERO REGISTRATION NUMBER: CRD42018093046.
No takes yet. Share an insight, caveat, or question.
Schmidt et al. (2019) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: